Seikagaku Corp.

Seikagaku Corp. specialises in synovial fluid supplementation media, specifically formulations like cross-linked hyaluronate and sodium hyaluronate. These devices are designed to be injected into joints to help restore lubrication and cushioning, primarily for osteoarthritis treatment. Examples include gel-based and liquid formulations, often delivered via pre-filled syringes.

Seikagaku Corp. is based in the United States, which means its devices are subject to FDA regulations. The company’s products are authorised through pathways like 510(k), PMA, and UDI listings, reflecting compliance with U.S. medical device classification standards. The FDA’s regulatory databases include entries for these devices, ensuring transparency in their authorised status.

Seikagaku Corp.’s devices appear in the FDA’s 510(k), PMA, and UDI registries because these pathways are used to authorise different classes of medical devices. Class I devices (generally low-risk) may require less stringent premarket review, while Class III devices (higher-risk) undergo rigorous evaluation via PMA. The UDI system ensures unique identification for traceability and compliance tracking.

Seikagaku Corp.’s devices are classified as either Class I or Class III under FDA regulations. Class I devices, like some synovial supplementation products, are typically low-risk and may only require general controls. Class III devices, which often involve higher-risk procedures or patient implants, require premarket approval (PMA) due to insufficient data from less stringent pathways, ensuring their safety and effectiveness.

The FDA assigns device classifications based on risk and intended use. Class III devices, such as certain synovial supplementation products, require PMA because they pose higher risks—like potential adverse reactions or lack of adequate safety data from less rigorous pathways. In contrast, Class I devices (e.g., some hyaluronate formulations) may qualify for 510(k) clearance if they can demonstrate substantial equivalence to a legally marketed predicate device, reducing regulatory burden for lower-risk products.